A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis - Metronidazole Versus lactic acId for Treating bacterial vAginosis–VITA

niversity Hospitals Birmingham NHS Foundation Trust0 个研究点目标入组 1,900 人开始时间: 2018年5月10日最近更新: 2020年10月13日

适应症

试验速览

暂无简介。

•1.Age 16 years or over.
•2.Clinical diagnosis of bacterial vaginosis – based on patient reported symptoms of discharge with an unpleasant (typically fishy) odour (with or without positive microscopy according to local site practice).
•3.History of at least one previous episode of bacterial vaginosis within the past two years (clinically diagnosed or patient reported) which resolved with treatment.
•4.Willing to use either intravaginal lactic acid gel or oral tablets for the management of BV.
•5.Willing to take their own vaginal samples.
•6.Willing to avoid vaginal douching during treatment.
•7.Willing to provide contact details and be contacted for the purpose of collecting follow-up information.
•8.Willing to avoid sexual intercourse or use effective contraception for the 7-day duration of study treatment. (Condoms are not considered to be effective contraception due to a potential interaction with lactic acid gel).
•9.Access to the internet, email and willing to complete web based follow up questionnaires in English.
•10.Written informed consent.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 95
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1710
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 95

•1.Contra-indications or allergy to lactic acid gel or metronidazole tablets (see section 4.2.1 for details).
•2.Pregnant or breastfeeding.
•3.Patients currently trying to conceive and not willing to avoid sexual intercourse or use effective contraception for the 7-day duration of study treatment.
•4.Use of oral antibiotics (other than the study treatment) or antifungal agents; concurrently, within the last 2 weeks or planned use within the next 2 weeks.
•5.Use of topical vaginal antibiotics, antifungals or acidifying products (other than the study treatment); concurrently, within the last 2 weeks, or planned use within the next 2 weeks.
•6.Previous participation in this study.
•7.Current participation in another clinical trial involving an investigational medicinal product.

发起方

niversity Hospitals Birmingham NHS Foundation Trust